
Annual report 2025
added 04-25-2026
Sundial Growers Net Income 2011-2026 | SNDL
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Sundial Growers
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -230 M | -240 M | -271 M | -13 M | -1.55 M | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.55 M | -271 M | -151 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Cumberland Pharmaceuticals
CPIX
|
-1.41 M | $ 6.45 | 9.88 % | $ 95.8 M | ||
|
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-5.35 M | - | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
-1.07 B | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-466 M | - | -0.1 % | $ 2.03 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
-14.3 M | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
-8.32 M | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
-20.1 M | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
-2.9 M | $ 2.74 | - | $ 1.05 B | ||
|
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
-5.14 M | $ 32.99 | -0.03 % | $ 1.21 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | ||
|
Pacira BioSciences
PCRX
|
-99.6 M | $ 23.61 | 1.11 % | $ 1.09 B | ||
|
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | ||
|
Bausch Health Companies
BHC
|
157 M | $ 5.52 | 0.91 % | $ 2.05 B | ||
|
Organogenesis Holdings
ORGO
|
37 M | $ 2.61 | -2.07 % | $ 331 M | ||
|
Canopy Growth Corporation
CGC
|
-598 M | $ 1.06 | 2.19 % | $ 114 M | ||
|
Solid Biosciences
SLDB
|
-174 M | $ 6.87 | 3.63 % | $ 601 M | ||
|
Aurora Cannabis
ACB
|
1.59 M | $ 3.5 | 1.16 % | $ 192 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-3.46 M | $ 1.08 | -1.82 % | $ 1.34 M | ||
|
Jupiter Wellness
JUPW
|
-68.2 M | - | - | $ 33.6 M | ||
|
Tilray
TLRY
|
-1.45 B | $ 5.47 | 3.4 % | $ 3.38 B | ||
|
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
-45.4 M | $ 1.14 | 1.34 % | $ 109 M | ||
|
Evolus
EOLS
|
-51.6 M | $ 6.07 | -0.33 % | $ 391 M | ||
|
Emergent BioSolutions
EBS
|
52.6 M | $ 8.92 | 5.56 % | $ 477 M | ||
|
Veru
VERU
|
-22.7 M | $ 2.37 | 0.85 % | $ 34.7 M | ||
|
Neoleukin Therapeutics
NLTX
|
-90.4 M | - | - | $ 193 M | ||
|
Assertio Holdings
ASRT
|
-30.4 M | $ 23.45 | 0.04 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
18.5 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | ||
|
cbdMD
YCBD
|
-2.04 M | $ 0.75 | -1.02 % | $ 3.02 M | ||
|
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
-57.4 M | $ 6.92 | -1.76 % | $ 273 M | ||
|
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
-35.5 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
-8.61 M | $ 0.72 | -1.82 % | $ 36 M | ||
|
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
-3.51 B | $ 16.49 | -0.99 % | $ 19.3 B | ||
|
Zomedica Corp.
ZOM
|
-81.9 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
-5.31 M | $ 0.77 | -2.98 % | $ 27.7 M | ||
|
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
-3.19 M | $ 0.79 | 4.63 % | $ 3.39 M | ||
|
TherapeuticsMD
TXMD
|
-569 K | $ 2.11 | -0.47 % | $ 24.4 M |